Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 5
2007 3
2008 3
2009 3
2010 6
2011 5
2012 7
2013 14
2014 10
2015 7
2016 10
2017 14
2018 10
2019 15
2020 15
2021 13
2022 8
2023 7
2024 10
2025 13
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R, van der Meulen NP. Müller C, et al. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919-1930. doi: 10.1007/s00259-019-04345-0. Epub 2019 May 27. Eur J Nucl Med Mol Imaging. 2019. PMID: 31134301 Free PMC article.
Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis.
Florit A, de Koster EJ, Sassano S, Alic L, Pisano G, van Velden FHP, Annunziata S, Primac I, Ruggiero MR, Müller C, Sala E, Fendler WP, Scambia G, de Geus-Oei LF, Fagotti A, Rufini V, Collarino A. Florit A, et al. Among authors: muller c. Eur J Nucl Med Mol Imaging. 2025 Sep;52(11):3975-3989. doi: 10.1007/s00259-025-07277-0. Epub 2025 Apr 25. Eur J Nucl Med Mol Imaging. 2025. PMID: 40278857 Free PMC article.
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.
Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, Geistlich S, Borgna F, Fani M, Bernhardt P, van der Meulen NP, Müller C, Schibli R, Wild D. Fricke J, et al. Among authors: muller c. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2517-2519. doi: 10.1007/s00259-024-06641-w. Epub 2024 Mar 7. Eur J Nucl Med Mol Imaging. 2024. PMID: 38448550 Free PMC article. No abstract available.
Targeted Radiotherapeutics from 'Bench-to-Bedside'.
Müller C, Béhé M, Geistlich S, van der Meulen NP, Schibli R. Müller C, et al. Chimia (Aarau). 2020 Dec 23;74(12):939-945. doi: 10.2533/chimia.2020.939. Chimia (Aarau). 2020. PMID: 33357286 Free article. Review.
Theranostics - a sure cure for cancer after 100 years?
Song Y, Zou J, Castellanos EA, Matsuura N, Ronald JA, Shuhendler A, Weber WA, Gilad AA, Müller C, Witney TH, Chen X. Song Y, et al. Among authors: muller c. Theranostics. 2024 Mar 31;14(6):2464-2488. doi: 10.7150/thno.96675. eCollection 2024. Theranostics. 2024. PMID: 38646648 Free PMC article. Review.
Single Photon Emission Computed Tomography Tracer.
Pietzsch HJ, Mamat C, Müller C, Schibli R. Pietzsch HJ, et al. Among authors: muller c. Recent Results Cancer Res. 2020;216:227-282. doi: 10.1007/978-3-030-42618-7_7. Recent Results Cancer Res. 2020. PMID: 32594389 Review.
156 results